الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 92 |  |  |
| | | from | 92 | | |
Abstract
This study aimed to assess serotonin transporter polymorphism in PDE-5 inhibitors non-responders. In all, 340 men presented to the University hospitals after ethical approval and informed consent.
They were allocated into:
Healthy potent men (n=170)
Men with ED non-responders for sildenafil (n=170)
Inclusion criteria for PDE-5Is non-responders:
An inadequate erectile response after 6 attempts using high tolerated dose (100 mg) with manufacturer’s guidelines in respect to time relative to meals, associated medications and sexual stimulation/ arousal.
Exclusion criteria:
Diabetes, smoking, hypertension, dyslipidemia, hypogonadism, cardiovascular disorders, morbid obesity and hepatic/renal failure.
They were subjected to:
History taking, clinical examination, IIEF-5 questionnaire and detection of 5-HTTLPR (serotonin transporter promoter gene) genotyping by PCR.
The results were as follows:
1. In potent controls, SS genotypes demonstrated significant increase whereas LL genotypes demonstrated significant decrease compared with ED men non-responders to sildenafil citrate.
2. SL/LL genotyping demonstrated significant increase in ED men non-responders to sildenafil citrate compared with potent men (relative risk 6.0).
3. In ED men non-responders for sildenafil citrate, the frequency of S allele demonstrated significant decrease and the frequency of L allele demonstrated significant increase compared with the potent controls.
4. 5-HTTLPR genotypes demonstrated significant negative correlation with IIEF-5 and significant positive correlation with age. IIEF-5 demonstrated significant negative correlation with age.
Conclusion:
5-HTTLPR polymorphism play a role of male sexual health being significantly represented in men with ED non-responding for sildenafil citrate.